| Literature DB >> 30961527 |
Yasunori Miyamoto1,2, Kouichi Hirayama3, Hiroshi Maruyama1, Kentaro Ohgi1, Mamiko Takayasu1, Homare Shimohata1, Masaki Kobayashi1.
Abstract
BACKGROUND: Thymic hyperplasia and thymic epithelial tumor (thymoma) have been associated with a variety of autoimmune diseases. Renal involvement has been reported in patients with thymoma. Minimal change disease and membranous nephropathy are frequently observed in glomerular lesions of thymoma patients, but ANCA-associated renal vasculitis is rare. We present a case of thymoma-associated microscopic polyangiitis with positivity for three ANCAs: MPO-ANCA, PR3-ANCA and azurocidin-ANCA. CASEEntities:
Keywords: Azurocidin-ANCA; MPO- ANCA; Microscopic polyangiitis; PR3-ANCA; Thymoma
Year: 2019 PMID: 30961527 PMCID: PMC6454690 DOI: 10.1186/s12882-019-1319-9
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1Clinical course of the present case. mPSL, methylprednisolone; PSL, prednisolone; RTX, rituximab. Solid black line: Serum MPO-ANCA levels. Solid gray line: Serum PR3-ANCA levels. Dotted black line: Serum creatinine levels
Fig. 2Renal histopathological findings in the present case. a Hematoxylin-eosin staining (40×). b Periodic acid-Schiff staining (200×). c Periodic acid-methenamine silver staining (400×). d Masson’s Trichrome staining (400×)
Fig. 3Findings of radiological examinations in the present case. a Chest CT. b Chest CT 2 months after the treatment. c Chest MRI, T1-weighted imaging coronal section. d Chest MRI T2-weighted imaging coronal section. Arrows indicate the lobulated tumor in the anterior mediastinum
Characteristics of ANCA-associated vasculitis complicated with thymoma (review)
| No. | authors | year | age sex | vasculitis | ANCA | other associated diseases | preced. diseases | laboratory data | renal pathology | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| class | organs | UP (g/d) | s-Alb (g/L) | s-Cr (mg/dL) | findings | class | |||||||
| 1 | Haberhauer G, et al. | 1993 | 22 F | NC | skin | perinuclear | PRCA | thymoma | NA | NA | NA | LC vasc. of skin | |
| 2 | Kobayashi M, et al. | 1995 | 47 F | absent | perinuclear | ITP, MG | same | NA | NA | NA | no vasculitis | ||
| 3 | Valli G, et al. | 1998 | 70 M | NC | kidney | NA | MG | thymoma | 3.9 | NA | 1.6 → 11.4 | ECPGN | mixed |
| 4 | Karras A, et al. | 2005 | 35 F | NC | kidney | NA | MG, PRCA | vasculitis | 1.8 | NA | 13.5 | ECPGN | NA |
| 5 | Karras A, et al. | 2005 | 65 M | NC | kidney | NA | MG | same | 1.0 | 35 | 1.69 | ECPGN | NA |
| 6 | Parambil JG, et al. | 2006 | 50 M | MPA | kidney | MPO | none | samea | 3.9 | NA | 3.5 | ECPGN | NA |
| 7 | Holmes MV, et al. | 2007 | 7 F | MPA | kidney | negative | MG | same vasculitis | NA | NA | NA | ECPGN | NA |
| 8 | the present case | 2018 | 89 F | MPA | kidney | MPO, PR3, azurocidin | MG | same | 2.1 | 29 | 2.17 | ECPGN | cres. |
F female, M male, NC not classified, ND not diagnosed, NA not available, EU ELISA units, PRCA pure red cell aplasia, ITP idiopathic thrombocytopenic purpura, MG myasthenia gravis, Preced precedence, UP urinary protein, S-Alb serum albumin; S-Cr serum creatinine; NA not available, LC vasc, leucocytoclastic vasculitis, ECPGN extracapillary proliferative glomerulonephritis; cres, crescentic
aVasculitis was exacerbated after thymectomy
Treatments of ANCA-associated vasculitis complicated with thymoma (review)
| No. | authors | year | thymectomy | thymic pathology | medication for vasculitis | outcome | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| findings | class | CS | CYC | others | remission | relapse | ||||
| 1 | Haberhauer G, et al. | 1993 | done | hyperplasia | + | – | NSAID | CR | relapse | |
| 2 | Kobayashi M, et al. | 1995 | done | non-invasive | B2 | 30 mg/d | – | G-CSFa | CRa | none |
| 3 | Valli G, et al. | 1998 | done | NA | NA | + | + | – | ESRD | NA |
| 4 | Karras A, et al. | 2005 | done | non-invasive | B2 | + | – | AZA | CR | NA |
| 5 | Karras A, et al. | 2005 | not done | + | – | – | PR | NA | ||
| 6 | Parambil JG, et al. | 2006 | done | non-invasive | B2 | 1.0 mg/kg/d | 2.0 mg/kg/d | AZA | CR | none |
| 7 | Holmes MV, et al. | 2007 | done | invasive | B1 | + | + | – | CR | NA |
| 8 | The present case | 2018 | not done | 1.0 mg/kg/d | – | Rituximab | ESRD | none | ||
CS corticosteroid, CYC cyclophosphamide, NSAID non-steroidal anti-inflammatory drugs, G-CSF granulocyte-colony stimulating factor, AZA azathioprine, CR complete remission, PR partial remission, ESRD end-stage renal disease, NA not available
aMedications and prognosis for granulocytopenia